LSV Asset Management Grows Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• LSV Asset Management increased its stake in Halozyme Therapeutics by 41.9% to own approximately 0.72% of the company, totaling $57.12 million worth of shares.
• Multiple institutional investors have also increased their positions in Halozyme, with 97.79% of the stock currently owned by such investors.
• Analysts have given mixed ratings for Halozyme shares, with a consensus rating of "Hold" and a target price of $62.70.

LSV Asset Management boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 41.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 895,191 shares of the biopharmaceutical company's stock after buying an additional 264,130 shares during the quarter. LSV Asset Management owned approximately 0.72% of Halozyme Therapeutics worth $57,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Heck Capital Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Bessemer Group Inc. boosted its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares during the period. Park Place Capital Corp boosted its stake in shares of Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 182 shares during the period. UMB Bank n.a. boosted its stake in shares of Halozyme Therapeutics by 267.4% during the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after purchasing an additional 960 shares during the period. Finally, CWM LLC boosted its stake in shares of Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after purchasing an additional 438 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $41,403,763.17. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 60,000 shares of company stock valued at $3,262,400 in the last ninety days. 2.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Morgan Stanley raised Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $62.00 to $75.00 in a research note on Wednesday. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Finally, The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 target price for the company. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and a consensus price target of $66.10.

Halozyme Therapeutics Stock Up 0.4%

HALO traded up $0.25 during trading on Thursday, reaching $62.57. The stock had a trading volume of 222,732 shares, compared to its average volume of 1,944,591. The stock's 50 day moving average is $55.69 and its two-hundred day moving average is $57.83. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The company has a market capitalization of $7.71 billion, a price-to-earnings ratio of 14.33, a P/E/G ratio of 0.41 and a beta of 1.17. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 142.12% and a net margin of 47.28%. The firm's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.91 earnings per share. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.